Mocetinostat Dihydrobromide

N/A

Report date: 2026/02/17 20:00:13
NME

Base Information

Drug NameMocetinostat Dihydrobromide
Drug Alias Namemocetinostat莫诺司他莫西司他MGCD-103MGCD-0103 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 1 inhibitors
TargetsHistone deacetylase 1
Therapy Area/IndicationsMyelodysplastic SyndromesProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMirati Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMirati Therapeutics Inc
Inactive CompaniesSarcoma Alliance For Research Through CollaborationMethylgene IncUniversity Health Network (Uhn)
Active IndicationsLung NeoplasmsRhabdomyosarcoma
Inactive IndicationsMyelodysplastic SyndromesProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[17] 

Other Information

ATC CodeN/A
Related LinksKEGG